Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.

Cancer - 15 Apr 2021

Kantarjian Hagop M, Kadia Tapan M, DiNardo Courtney D, Welch Mary Alma, Ravandi Farhad

Abstract excerpt

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has approved nine agents for different AML treatment indications since 2017. In this review, we detail the progress that has been made in the research and treatment of AML,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to Cytarabine

Share to Daunorubicin

Share to Leukemia, Promyelocytic, Acute

Share to Maintenance Chemotherapy

Share to Vidarabine

Source

Identifiers

PMID: 33734442
DOI: 10.1002/cncr.33477

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.PMID 33734442Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.Semantic proximity Read ↗

Acute myeloid leukemiaSemantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

Advances in acute myeloid leukemia.Semantic proximity Read ↗

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read ↗

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia.Semantic proximity Read ↗

‘Acute myeloid leukemia: a comprehensive review and 2016 update’Semantic proximity Read ↗

Classification of acute myeloid leukemiaSemantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.